1. Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. (3rd January 2016) Authors: Mesa, Ruben; Verstovsek, Srdan; Kiladjian, Jean‐Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Zhen, Huiling; Jones, Mark M.; Parasuraman, Shreekant; Li, Jingjin; Côté, Isabelle; Habr, Dany; Vannucchi, Ales... Journal: European journal of haematology Issue: Volume 97:Number 2(2016:Aug.) Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF). (8th November 2016) Authors: Mesa, Ruben; Vannucchi, Alessandro M.; Yacoub, Abdulraheem; Zachee, Pierre; Garg, Mamta; Lyons, Roger; Koschmieder, Steffen; Rinaldi, Ciro; Byrne, Jennifer; Hasan, Yasmin; Passamonti, Francesco; Verstovsek, Srdan; Hunter, Deborah; Jones, Mark M.; Zhen, Huiling; Habr, Dany; Martino, Bruno Journal: British journal of haematology Issue: Volume 176:Number 1(2017) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Issue 5 (May 2020) Authors: Abou-Alfa, Ghassan K; Sahai, Vaibhav; Hollebecque, Antoine; Vaccaro, Gina; Melisi, Davide; Al-Rajabi, Raed; Paulson, Andrew S; Borad, Mitesh J; Gallinson, David; Murphy, Adrian G; Oh, Do-Youn; Dotan, Efrat; Catenacci, Daniel V; Van Cutsem, Eric; Ji, Tao; Lihou, Christine F; Zhen, Huiling; Féliz, ... Journal: Lancet oncology Issue: Volume 21:Issue 5(2020) Page Start: 671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors. (16th August 2018) Authors: Beatty, Gregory L.; Shahda, Safi; Beck, Thaddeus; Uppal, Nikhil; Cohen, Steven J.; Donehower, Ross; Gabayan, Afshin Eli; Assad, Albert; Switzky, Julie; Zhen, Huiling; Von Hoff, Daniel D. Journal: Oncologist Issue: Volume 24:Number 1(2019) Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P18 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202. (20th September 2022) Authors: Vogel, Arndt; Sahai, Vaibhav; Hollebecque, Antoine; Vaccaro, Gina M; Melisi, Davide; Rajabi, Raed MAl; Paulson, Andrew S; Borad, Mitesh J; Gallinson, David; Murphy, Adrian G; Oh, Do-Youn; Dotan, Efrat; Catenacci, Daniel V; Cutsem, Eric Van; Lihou, Christine F; Zhen, Huiling; Veronese, Luisa; Abou... Journal: Gut Issue: Volume 71(2022)Supplement 3 Page Start: A44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗